The Kinetic Interpretation of the DGLAP Equation, its Kramers-Moyal Expansion and Positivity of Helicity Distributions

According to a rederivation - due to Collins and Qiu - the DGLAP equation can be reinterpreted (in leading order) in a probabilistic way. This form of the equation has been used indirectly to prove the bound $|\Delta f(x,Q)| < f(x,Q)$ between polarized and unpolarized distributions, or positivity of the helicity distributions, for any $Q$. We reanalize this issue by performing a detailed numerical study of the positivity bounds of the helicity distributions. To obtain the numerical solution we implement an x-space based algorithm for polarized and unpolarized distributions to next-to-leading order in $\alpha_s$, which we illustrate. We also elaborate on some of the formal properties of the Collins-Qiu form and comment on the underlying regularization, introduce a Kramers-Moyal expansion of the equation and briefly analize its Fokker-Planck approximation. These follow quite naturally once the master version is given. We illustrate this expansion both for the valence quark distribution $q_V$ and for the transverse spin distribution $h_1$.Comment: 38 pages, 27 figures, Dedicated to Prof. Pierre Ramond for his 60th birthda

Complete Next to Leading Order QCD Corrections to the Photon Structure Functions F2γ(x,Q2)F^\gamma_2(x,Q^2) and FLγ(x,Q2)F_L^\gamma(x,Q^2)

We present the complete NLO QCD analysis of the photon structure functions $F_2^\gamma(x,Q^2)$ and $F_L^\gamma(x,Q^2)$ for a real photon target. In particular we study the heavy flavor content of the structure functions which is due to two different production mechanisms, namely collisions of a virtual photon with a real photon, and with a parton. We observe that the charm contributions are noticeable for $F_2^\gamma(x,Q^2)$ as well as $F_L^\gamma(x,Q^2)$ in the x-region studied.Comment: Latex 34 pages, 24 figures, uuencoded, attached at end, ITP-SB-93-46, FERMILAB-Pub-93/240-T, SMU HEP 93-1

Resolved Photon Processes

We review the present level of knowledge of the hadronic structure of the photon, as revealed in interactions involving quarks and gluons ``in" the photon. The concept of photon structure functions is introduced in the description of deep--inelastic $e \gamma$ scattering, and existing parametrizations of the parton densities in the photon are reviewed. We then turn to hard \gamp\ and \gaga\ collisions, where we treat the production of jets, heavy quarks, hard (direct) photons, \jpsi\ mesons, and lepton pairs. We also comment on issues that go beyond perturbation theory, including recent attempts at a comprehensive description of both hard and soft \gamp\ and \gaga\ interactions. We conclude with a list of open problems.Comment: LaTeX with equation.sty, 85 pages, 29 figures (not included). A complete PS file of the paper, including figures, can be obtained via anonymous ftp from ftp://phenom.physics.wisc.edu/pub/preprints/1995/madph-95-898.ps.

Theory of hard photoproduction

The present theoretical knowledge about photons and hard photoproduction processes, i.e. the production of jets, light and heavy hadrons, quarkonia, and prompt photons in photon-photon and photon-hadron collisions, is reviewed. Virtual and polarized photons and prompt photon production in hadron collisions are also discussed. The most important leading and next-to-leading order QCD results are compiled in analytic form. A large variety of numerical predictions is compared to data from TRISTAN, LEP, and HERA and extended to future electron and muon colliders. The sources of all relevant results are collected in a rich bibliography.Comment: Habilitationsschrift, scheduled for publication in Rev. Mod. Phys., 126 pages, 61 figure

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Photography-based taxonomy is inadequate, unnecessary, and potentially harmful for biological sciences

The question whether taxonomic descriptions naming new animal species without type specimen(s) deposited in collections should be accepted for publication by scientific journals and allowed by the Code has already been discussed in Zootaxa (Dubois & Nemésio 2007; Donegan 2008, 2009; Nemésio 2009a–b; Dubois 2009; Gentile & Snell 2009; Minelli 2009; Cianferoni & Bartolozzi 2016; Amorim et al. 2016). This question was again raised in a letter supported by 35 signatories published in the journal Nature (Pape et al. 2016) on 15 September 2016. On 25 September 2016, the following rebuttal (strictly limited to 300 words as per the editorial rules of Nature) was submitted to Nature, which on 18 October 2016 refused to publish it. As we think this problem is a very important one for zoological taxonomy, this text is published here exactly as submitted to Nature, followed by the list of the 493 taxonomists and collection-based researchers who signed it in the short time span from 20 September to 6 October 2016